<DOC>
	<DOCNO>NCT02285478</DOCNO>
	<brief_summary>Darunavir/ritonavir one prefer antiretroviral agent part combination antiretroviral therapy treatment HIV-infected adult accord international guideline . For child 3-12 year old , FDA approve daily dose darunavir/ritonavir . Dosing recommendation child 6-12 year old approve base model simulation procedure company . This pharmacokinetic study design validate propose dose recommendation daily darunavir/ritonavir HIV-infected child age 6-12 year old .</brief_summary>
	<brief_title>Pharmacokinetics Once Daily Darunavir/Ritonavir HIV-infected Children</brief_title>
	<detailed_description>The EMA FDA recommend weight band dose daily DRV/r dose child 3 -12 year age derive pharmacokinetic modelling . Results population pharmacokinetic modelling simulation child predict similar DRV plasma exposure compare treatment-na√Øve adult , formally study target population . Although clinical trial conduct collect exposure-safety data , predict exposure daily dose supported exposure observe paediatric clinical trial twice-daily dose administer . To validate weight band base dose recommendation , want evaluate pharmacokinetics DRV/r administer daily , use DRV tablet , HIV-infected child . Darunavir/ritonavir one prefer antiretroviral agent part combination antiretroviral therapy treatment HIV-infected adult accord international guideline . For child 3-12 year old , FDA approve daily dose darunavir/ritonavir . Dosing recommendation child 6-12 year old approve base model simulation procedure company . This pharmacokinetic study design validate propose dose recommendation daily darunavir/ritonavir HIV-infected child age 6-12 year old .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<criteria>1 . Parents/carers able willing sign inform consent form prior screen evaluation 2 . Subject HIV infect 3 . Subject least 6 less 12 year day screen 4 . Subject body weight least 15kg 5 . Subject able swallow tablet 6 . Subject undetectable viral load ( &lt; 50 copies/mL ) last 6 month prior screen ( least 2 measurement ) 7 . ART regimen consist darunavir/ritonavir 2 NRTIs 1 . Inability understand nature extent trial procedure require 2 . Documented history sensitivity/idiosyncrasy darunavir ritonavir medicinal product excipients 3 . Relevant history current condition might interfere drug absorption , distribution , metabolism excretion 4 . Abnormal renal liver function ( grade 3 ) 5 . Participation drug trial within 60 day prior first dose 6 . Hemoglobin &lt; 10 g/dL ( 6.0 mmol/L ) 7 . Children previously fail virologically PI contain regimen ( virological failure define two successive HIV1 RNA result &gt; 1,000 c/mL 24 week start cART , i.e . change toxicity convenience counted failure ) 8 . Acute illness 9 . Receiving concomitant therapy except prophylaxis opportunistic infection ; treatment may allow , must first discuss principal investigator project manager .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>